AtheroGenics to Report First Quarter 2008 Financial Results on April 24, 2008
17 Abril 2008 - 10:18AM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, today announced that it will
release its first quarter 2008 financial results on Thursday, April
24, 2008 before the U.S. financial markets open.
Conference Call and Webcast Information
Company officials will discuss first quarter 2008 financial
results via conference call and webcast on Thursday, April 24,
2008, at 9:00 a.m. EDT. Participants may access the live conference
call by dialing 877-407-8031 (domestic) or 201-689-8031
(international). To access the webcast, please visit the
AtheroGenics Investor Relations website at www.atherogenics.com. A
replay of the conference call will be accessible approximately one
hour after the conclusion of the call by dialing 877-660-6853
(domestic) or 201-612-7415 (international), account number 286,
conference ID number 281784. A replay of the webcast will be
archived on the Company's website until July 25, 2008.
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). The Company's lead product candidate,
AGI-1067, is a novel antioxidant and anti-inflammatory agent that
is currently being evaluated in a Phase III registration study
called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation
Study) as an oral treatment for Type 2 diabetes. In addition, the
Company has other clinical and preclinical anti-inflammatory
compounds, including AGI-1096, an oral agent for the prevention of
organ transplant rejection. For more information about
AtheroGenics, please visit http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Donna L. Glasky Corporate
Communications 678-336-2517 Email Contact Media Inquiries Jayme
Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770
Email Contact Investor Inquiries Lilian Stern Stern Investor
Relations, Inc. 212-362-1200 Email Contact
Atherogenics (NASDAQ:AGIX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Atherogenics (NASDAQ:AGIX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Atherogenics (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de AtheroGenics, Inc.